FDA grants priority review to Dupixent® (dupilumab) sBLA for treating teens with chronic rhinosinusitis and nasal polyps.

Cardurion Pharmaceuticals Reports Encouraging Outcomes from Phase 2a CARDINAL-HF Study of PDE9 Inhibitor in Heart Failure Patients.

Anaptys released encouraging initial outcomes from the GEMINI-2 Phase 3 study of Imsidolimab (IL-36R) for treating Generalized Pustular Psoriasis.

First Wave will concentrate on advancing a portfolio of gastrointestinal disease therapies, including latiglutenase, which encompasses multiples late-stage clinical assets.

Fusion Pharmaceuticals revealed that the initial participant has received a dose in the AlphaBreak Trial's Phase 2 study of FPI-2265 for treating metastatic castration-resistant prostate cancer.

Celltrion USA now offers a budget-friendly adalimumab-aaty biosimilar as an alternative to HUMIRA® at reduced wholesale prices.

X4 Pharmaceuticals is a biotech company specialized in the development of therapeutic drugs focusing on CXCR4 and immunological biology.

WestGene proudly declares a significant breakthrough as the FDA grants IND approval for its mRNA-based cancer vaccine, WGc-043.

PeptiDream is a biotechnology company based in Japan, focused on the development of innovative macrocyclic peptide drugs.

Revance Therapeutics, Inc. has initiated the market release of DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, aimed at treating cervical dystonia.

Shionogi & Co., Ltd. along with Maze Therapeutics, Inc. have declared a global exclusive licensing deal for MZE001, an innovative therapy aimed at addressing Pompe Disease.

May 14th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.